Project 3. Cyclic nucleotides (cAMP and cGMP) are intracellular signaling molecules that are critical for the development and function ofthe brain. Deficits in cAMP/cGMP signaling have been repeatedly measured in patients with Alzheimer's disease and schizophrenia. Dysfunction ofthe hippocampus (HIPP) - a brain region that modulates affective, social, stress-related, and cognitive behaviors - has also been repeatedly implicated in these neuropsychiatric diseases. We believe that selectively restoring cyclic nucleotide signaling in the HIPP of patients, without affecting signaling in normal brain regions, would relieve neuropsychiatric disease-related symptoms without causing unwanted side effects. Phosphodiesterase 11A (PDE11A) is an enzyme that breaks down both cAMP and cGMP. We have recently discovered that PDE11A is almost exclusively localized to the HIPP. Thus, we hypothesize that cAMP/cGMP signaling in the HIPP can be selectively targeted by modulating PDE11A expression and/or function. Adult PDE11A knockout (KO) mice exhibit biochemical, anatomical, and behavioral deficits that are consistent with HIPP dysfunction and neuropsychiatric disease. This suggests that augmentation of PDE11A function may prove therapeutic. To increase function of a particular enzyme, we can increase either its availability (i.e., expression) or its catalytic activity. As such, we propose a series of aims designed to understand the molecular mechanisms controlling transcription and catalytic activity of PDE11 A.
In Specific Aim 1, we will determine if psychiatric disease is associated with changes in PDE11A transcription in brain and if cis-acting elements within the promoter of PDE11A are sufficient to restrict PDE11A mRNA expression to the HIPP in the healthy adult brain.
In Specific Aim 2, we will identify the signaling cascades and trans-acting proteins that control PDE11A promoter activity.
In Specific Aim 3, we will develop small molecule PDE11A activators and test them in PDE11A wild-type and KO mice (KOs = negative controls) using a neuropsychiatric battery that assesses efficacy and side effect liability. PDE11A may be capable of selectively restoring cAMP and cGMP signaling in a specific brain region impacted by disease, without affecting signaling elsewhere.

Public Health Relevance

Deficits in cAMP and cGMP signaling have been repeatedly measured in patients with Alzheimer's disease and schizophrenia. This proposal seeks to better understand how we can control the transcription and catalytic activity of Phosphodiesterase 11 A, an enzyme that breaks down cAMP and cGMP. In so doing, we hope to identify a therapeutic path forward to rescue the cAMP and cGMP deficits associated with neuropsychiatric diseases

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
1P20GM109091-01
Application #
8653311
Study Section
Special Emphasis Panel (ZGM1-TWD-A (C1))
Project Start
Project End
Budget Start
2014-07-10
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$219,750
Indirect Cost
$69,750
Name
University of South Carolina at Columbia
Department
Type
DUNS #
041387846
City
Columbia
State
SC
Country
United States
Zip Code
29208
Jenkins, Laura M; Singh, Priyanka; Varadaraj, Archana et al. (2016) Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem 291:25716-25728
Piroli, Gerardo G; Manuel, Allison M; Clapper, Anna C et al. (2016) Succination is Increased on Select Proteins in the Brainstem of the NADH dehydrogenase (ubiquinone) Fe-S protein 4 (Ndufs4) Knockout Mouse, a Model of Leigh Syndrome. Mol Cell Proteomics 15:445-61
Jeong, Ha-Won; Choi, Ran Hee; McClellan, Jamie L et al. (2016) Tribbles 3 inhibits brown adipocyte differentiation and function by suppressing insulin signaling. Biochem Biophys Res Commun 470:783-91
Cheng, Bei; He, Huacheng; Huang, Tao et al. (2016) Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. J Biomed Nanotechnol 12:435-49
Hegde, Shweta; Ji, Hao; Oliver, David et al. (2016) PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain. Neuroscience 335:151-69
He, Huacheng; Altomare, Diego; Ozer, Ufuk et al. (2016) Cancer cell-selective killing polymer/copper combination. Biomater Sci 4:115-20
Rai, R; Zhang, F; Colavita, K et al. (2016) Arginyltransferase suppresses cell tumorigenic potential and inversely correlates with metastases in human cancers. Oncogene 35:4058-68
Kindy, Mark S; Yu, Jin; Zhu, Hong et al. (2016) A therapeutic cancer vaccine against GL261 murine glioma. J Transl Med 14:1
Broude, Eugenia V; Győrffy, Balázs; Chumanevich, Alexander A et al. (2015) Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. Curr Cancer Drug Targets 15:739-49
Gomez, Adrian M; Altomare, Diego; Sun, Wei-Lun et al. (2015) Prefrontal microRNA-221 Mediates Environmental Enrichment-Induced Increase of Locomotor Sensitivity to Nicotine. Int J Neuropsychopharmacol 19:

Showing the most recent 10 out of 20 publications